| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $1,241,420 ) |
| | 2024 | 2024 | FIBRONOX, L.L.C. | 1001 E 17TH ST | TUCSON | AZ | 85719-6769 | PIMA | USA | R41HL174346 | Repurposing of FDA-approved Nrf2 Activators as a Novel Inhaled Therapy for Pulmonary Fibrosis | 000 | 1 | NIH | 5/10/2024 | $286,739 |
| | 2024 | 2024 | FIBRONOX, L.L.C. | 1001 E 17TH ST | TUCSON | AZ | 85719-6769 | PIMA | USA | R44HL172475 | Advanced Pre-clinical development of Nox4 inhibitors for Pulmonary Fibrosis | 000 | 1 | NIH | 5/31/2024 | $954,681 |
| | 2024 | 2024 | FIBRONOX, L.L.C. | 1001 E 17TH ST | TUCSON | AZ | 85719-6769 | PIMA | USA | R44HL172475 | Advanced Pre-clinical development of Nox4 inhibitors for Pulmonary Fibrosis | 001 | 1 | NIH | 8/7/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2020 | FIBRONOX, L.L.C. | 1001 E 17TH ST | TUCSON | AZ | 85719-6769 | PIMA | USA | R41HL151043 | Therapeutic targeting of Nox2 and Nox4 in Duchenne Muscular Dystrophy | 000 | 1 | NIH | 9/12/2023 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2020 | FIBRONOX, L.L.C. | 195 13TH ST NE UNIT 1804 | ATLANTA | GA | 30309-5039 | FULTON | USA | R41HL151043 | Therapeutic targeting of Nox2 and Nox4 in Duchenne Muscular Dystrophy | 000 | 1 | NIH | 4/6/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $248,019 ) |
| | 2020 | 2020 | FIBRONOX, L.L.C. | 1001 E 17TH ST APT 117 | TUCSON | AZ | 85719-6769 | PIMA | USA | R41HL151043 | Therapeutic targeting of Nox2 and Nox4 in Duchenne Muscular Dystrophy | 000 | 1 | NIH | 9/4/2020 | $248,019 |
|
|
